

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2023 December 15; 15(12): 2049-2241



EDITORIAL

- 2049 Dual primary gastric and colorectal cancer: A complex challenge in surgical oncology
Marano L

MINIREVIEWS

- 2053 Identification of genes associated with gall bladder cell carcinogenesis: Implications in targeted therapy of gall bladder cancer
Ghosh I, Dey Ghosh R, Mukhopadhyay S

ORIGINAL ARTICLE**Clinical and Translational Research**

- 2064 Transient receptor potential-related risk model predicts prognosis of hepatocellular carcinoma patients
Mei XC, Chen Q, Zuo S

Retrospective Cohort Study

- 2077 Cohort study to assess geographical variation in cholangiocarcinoma treatment in England
Jose S, Zalin-Miller A, Knott C, Paley L, Tataru D, Morement H, Toledano MB, Khan SA

Retrospective Study

- 2093 Effect of ultrasound-guided lumbar square muscle block on stress response in patients undergoing radical gastric cancer surgery
Wang XR, Xu DD, Guo MJ, Wang YX, Zhang M, Zhu DX

- 2101 Application of remimazolam transversus abdominis plane block in gastrointestinal tumor surgery
Liu J, Tian JM, Liu GZ, Sun JN, Gao PF, Zhang YQ, Yue XQ

- 2111 The efficacy of full-thickness endoscopic resection of subepithelial tumors in the gastric cardia
Xu EP, Qi ZP, Li B, Ren Z, Cai MY, Cai SL, Lyv ZT, Chen ZH, Liu JY, Shi Q, Zhong YS

Basic Study

- 2120 Hsa_circ_0136666 mediates the antitumor effect of curcumin in colorectal carcinoma by regulating CXCL1 via miR-1301-3p

Chen S, Li W, Ning CG, Wang F, Wang LX, Liao C, Sun F

- 2138 Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses

Zhang XS, Zhou HC, Wei P, Chen L, Ma WH, Ding L, Liang SC, Chen BD

- 2150** Association between heat shock factor protein 4 methylation and colorectal cancer risk and potential molecular mechanisms: A bioinformatics study
Zhang WJ, Yue KL, Wang JZ, Zhang Y
- 2169** Evaluating the causal relationship between human blood metabolites and gastroesophageal reflux disease
Hu JY, Lv M, Zhang KL, Qiao XY, Wang YX, Wang FY
- 2185** Paired-related homeobox 1 induces epithelial-mesenchymal transition in oesophageal squamous cancer
Guo JB, Du M, Wang B, Zhong L, Fu ZX, Wei JL

META-ANALYSIS

- 2197** Intensive follow-up *vs* conventional follow-up for patients with non-metastatic colorectal cancer treated with curative intent: A meta-analysis
Cui LL, Cui SQ, Qu Z, Ren ZQ
- 2212** Prognostic value of T cell immunoglobulin and mucin-domain containing-3 expression in upper gastrointestinal tract tumors: A meta-analysis
Yan JJ, Liu BB, Yang Y, Liu MR, Wang H, Deng ZQ, Zhang ZW
- 2225** Association of MBOAT7 rs641738 polymorphism with hepatocellular carcinoma susceptibility: A systematic review and meta-analysis
Lai M, Qin YL, Jin QY, Chen WJ, Hu J

CASE REPORT

- 2237** Conversion immunotherapy for deficient mismatch repair locally unresectable colon cancer: A case report
Sun Z, Liu H, Zhang GN, Xiao Y

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Luigi Marano, MD, PhD, Professor, Department of Medicine, Academy of Medical and Social Applied Sciences-AMiSNS: Akademia Medycznych i Społecznych Nauk Stosowanych-2 Lotnicza Street, Elbląg 82-300, Poland. l.marano@amisns.edu.pl

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (*WJGO*, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

INDEXING/ABSTRACTING

The *WJGO* is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJGO* as 3.0; IF without journal self cites: 2.9; 5-year IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The *WJGO*'s CiteScore for 2022 is 4.1 and Scopus CiteScore rank 2022: Gastroenterology is 71/149; Oncology is 197/366.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Xiang-Di Zhang; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

PUBLICATION DATE

December 15, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Retrospective Study

The efficacy of full-thickness endoscopic resection of subepithelial tumors in the gastric cardia

En-Pan Xu, Zhi-Peng Qi, Bing Li, Zhong Ren, Ming-Yan Cai, Shi-Lun Cai, Zhen-Tao Lyv, Zhang-Han Chen, Jing-Yi Liu, Qiang Shi, Yun-Shi Zhong

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Langner C, Austria;
Milone M, Italy

Received: September 10, 2023

Peer-review started: September 10, 2023

First decision: October 13, 2023

Revised: October 18, 2023

Accepted: October 30, 2023

Article in press: October 30, 2023

Published online: December 15, 2023



En-Pan Xu, Zhi-Peng Qi, Bing Li, Zhong Ren, Ming-Yan Cai, Shi-Lun Cai, Zhen-Tao Lyv, Zhang-Han Chen, Jing-Yi Liu, Qiang Shi, Yun-Shi Zhong, Endoscopy Center, Zhongshan Hospital Fudan University, Shanghai 200032, China

Corresponding author: Yun-Shi Zhong, MD, PhD, Doctor, Surgeon, Endoscopy Center, Zhongshan Hospital Fudan University, No. 180 Fenglin Road, Shanghai 200032, China.
zhong.yunshi@zs-hospital.sh.cn

Abstract

BACKGROUND

Gastric subepithelial tumors (SETs) may harbor potential malignancy. Although it is well recognized that large SETs should be resected, the precise treatment strategy remains controversial. Compared to surgical resection, endoscopic resection (ER) has many advantages; however, ER of SETs in the cardia is challenging.

AIM

To evaluate the safety and efficacy of endoscopic full-thickness resection (EFTR) for the treatment of gastric cardia SETs.

METHODS

We retrospectively reviewed data from all patients with SETs originating from the muscularis propria layer in the gastric cardia that were treated by EFTR or submucosal tunneling ER (STER) at Zhongshan Hospital Fudan University between November 2014 and May 2022. Baseline characteristics and clinical outcomes, including procedure times and complications rates, were compared between groups of patients receiving EFTR and STER.

RESULTS

A total of 171 tumors were successfully removed [71 (41.5%) tumors in the EFTR and 100 (58.5%) tumors in the STER group]. Gastrointestinal stromal tumors (GISTs) were the most common SET. The en bloc resection rate was 100% in the EFTR group *vs* 97.0% in STER group ($P > 0.05$). Overall, the EFTR group had a higher complete resection rate than the STER group (98.6% *vs* 91.0%, $P < 0.05$). The procedure time was also shorter in the EFTR group (44.63 ± 28.66 min *vs* 53.36 ± 27.34 , $P < 0.05$). The most common major complication in both groups was electrocoagulation syndrome. There was no significant difference in total complica-

ations between the two groups (21.1% *vs* 22.0%, $P = 0.89$).

CONCLUSION

EFTR of gastric cardia SETs is a very promising method to facilitate complete resection with similar complications and reduced operative times compared to STER. In cases of suspected GISTs or an unclear diagnosis, EFTR should be recommended to ensure complete resection.

Key Words: Endoscopic full-thickness resection; Submucosal tunneling endoscopic resection; Gastrointestinal stromal tumor; Gastric cardia; Gastric subepithelial tumors

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Efficacy of endoscopic full-thickness resection (EFTR) is safe and effective in the treatment of cardiac subepithelial tumors. Compared with submucosal tunneling endoscopic resection, EFTR can better completely resect subepithelial tumors and provide a better pathological diagnosis. When lesions with a high index of suspicion for gastrointestinal stromal tumors are found or there is an unclear diagnosis, EFTR should be recommended to ensure complete resection.

Citation: Xu EP, Qi ZP, Li B, Ren Z, Cai MY, Cai SL, Lyv ZT, Chen ZH, Liu JY, Shi Q, Zhong YS. The efficacy of full-thickness endoscopic resection of subepithelial tumors in the gastric cardia. *World J Gastrointest Oncol* 2023; 15(12): 2111-2119

URL: <https://www.wjgnet.com/1948-5204/full/v15/i12/2111.htm>

DOI: <https://dx.doi.org/10.4251/wjgo.v15.i12.2111>

INTRODUCTION

Gastric subepithelial tumors (SETs) are rare, accounting for less than 2% of all gastric tumors[1]. This group is comprised of different pathologies, commonly correlating with their location. Benign SETs are more frequently found in the cardia than in other locations[2].

With technological advancements, laparoscopic wedge resection is currently considered the best option for the treatment of gastric SETs[3]; however, it is difficult to resect SETs locating in the cardia and is associated with several complications, including leak, stenosis, and reflux[4,5]. Due to their typically benign nature and these postoperative risks, surgical resection of small, benign SETs is typically not mandatory.

Since the advent of submucosal tunneling endoscopic resection (ER) (STER), it has been widely used for SETs resection in the esophagus and cardia, and has achieved positive results[6-8]. The American Gastroenterological Association Clinical Practice Guidelines recommend using ER techniques to remove SETs[9]; however, in clinical application, damage to the tunneled surface mucosa may occur. This may be due to a large tumor and/or a lesion located in the deep layer of the muscularis propria (MP) (or even outside the cavity) or if the operating space in the tunnel is small, or the tunnel cannot be established at the tumor site. Additionally, submucosal fibrosis can lead to technical difficulty and tunnel establishment failure can occur.

Endoscopic full-thickness resection (EFTR) is a new surgical method of repairing the gastric wall after full-thickness resection so that endoscopic surgery is no longer limited by the depth of the tumor and submucosal fibrosis[10]. In 2009, EFTR without laparoscopic assistance for the treatment of gastrointestinal SET was first proposed. Since then, EFTR has been developed and widely applied clinically. Li *et al*[11] reported using dental floss and a hemoclip for assisted EFTR for SETs in the gastric fundus and demonstrated advantages in reducing surgical time and occurrence of post-endoscopic submucosal dissection (ESD) electrocoagulation syndrome (PEECS). Many studies have also proven that EFTR is safe and effective in the treatment of gastric SETs[12,13]; however, data regarding the clinical outcomes of EFTR for gastric cardia SETs are limited. Therefore, we evaluated the clinical outcomes of gastric cardia SETs treated by EFTR resection at our institution.

MATERIALS AND METHODS

Patients

We collected and reviewed data from patients with SETs originating from the MP layer in the gastric cardia, which were treated by EFTR or STER at Zhongshan Hospital Fudan University (Shanghai, China) between November 2014 and May 2022. The inclusion criteria were: (1) Proven diagnosis of SET by gastroscopy, endoscopic ultrasonography (EUS), and computed tomography (CT); (2) eligibility for endoscopic treatment; (3) lesion located in the cardia; and (4) final application of STER or EFTR. The exclusion criteria were: (1) Patients disagreement regarding resection; (2) malignant tumors with metastasis; and (3) coagulation disorders.

Informed patient consent was obtained from all patients. The study and procedures were conducted in accordance with the ethical standards of the Helsinki Declaration of 1975. This study was approved by the Institutional Review Board of Zhongshan Hospital (reference number: B2020-265).

EFTR and STER

EUS and/or CT were used to characterize the lesions in terms of size and other features prior to EFTR or STER. All patients were airway intubated under intravenous anesthesia, while vital signs were monitored. The ER method was selected based on the tumor characteristics. If the tumor deviates to the esophageal side, STER is used, and if the tumor deviates to the stomach side, EFTR is used. Some cases underwent EFTR while others underwent STER according to the patient's preference, after being informed of the merits and disadvantages of each technique. Description of the specific resection procedures can be found in the literature previously published by our center (Figure 1)[7,10].

Definitions

The surgical operator was categorized as a trainee with experience of 25 EFTR and STER procedures per year or as an expert with experience of > 25 procedures per year[11]. All were certified EFTR endoscopists. En bloc resection was characterized as the complete removal of a tumor without fragmentation. Complete resection was characterized as the en bloc removal of a lesion with the tumor extracted in a single piece and the capsule remaining intact[7]. Postoperative bleeding was characterized as hematemesis or melena within 14 d after completion of EFTR or STER. Hydrothorax was excess fluid in the pleural space, as confirmed by chest X-ray. Pneumoperitoneum was diagnosed by the presence of gas in the peritoneal cavity, observable on either X-ray or CT scan. Minor cases of pneumoperitoneum and minor hydrothorax had negligible clinical impact or symptoms and did not necessitate therapeutic intervention. Similar to PEECS, included as a minor complication here, was defined as fever (> 37.7 °C) and abdominal pain with localized tenderness without perforation confirmed by radiological exam within 7 d after EFTR or STER.

Follow up

Data were initially collected from medical records in our hospital. If patients have been discharged from our hospital, we make an effort to gather outcome information by contacting the patient or a family member by telephone. The minimum follow-up duration is 12 mo.

Statistical analysis

SPSS 21.0 software (IBM Corp, Armonk, NY, United States) was used for analysis. We compared categorical variables with the chi-square or Fisher's exact test. The Student's *t*-test or analysis of variance was used to compare continuous variables. Statistical analysis of independent risk factors for long operative times was assessed using a combination of univariate and multivariate analyses. A two-tailed *P* value < 0.05 was considered statistically significant.

RESULTS

Baseline characteristics

A total of 171 patients with SETs in the cardia were included in the study. Seventy-one (41.5%) patients underwent EFTR, while 100 (58.5%) received STER treatment. The clinical characteristics of these patients are presented in Table 1. The mean age of the EFTR and STER group was 51.32 ± 12.44 (median: 52; range: 43–61 years) and 50.29 ± 12.19 years (median: 51; range: 41–60 years), respectively. The average tumor size of the EFTR and STER group was 2.16 ± 1.81 cm (median: 1.5; range: 1.0–3.0 cm) and 2.09 ± 1.38 cm (median: 1.5; range: 1.2–2.5 cm), respectively. Six (8.5%) and 5 (5.0%) tumors showed extraluminal growth in the EFTR and STER groups. 59 (83.1%) patients underwent EFTR by expert surgeons, and 85 (85%) patients underwent EFTR by trainee surgeons. Patient characteristics and clinical data relating to tumors and procedures were similar between the EFTR and STER groups.

Outcome

The primary surgery-related outcomes from the two groups of patients are described in Table 2. All gastric cardia SETs were resected by ER. The en bloc resection rate was 100% in the EFTR group. There was no significant difference between the groups. EFTR had a higher completed resection rate than STER (98.6% vs 91.0%, *P* < 0.05). The procedure time was also shorter in the EFTR group (44.63 ± 28.66 min vs 53.36 ± 27.34, *P* < 0.05). In the EFTR group, there were 28 (39.4%) gastrointestinal stromal tumors (GISTs) and 43 (60.6%) leiomyomas. In the STER group, there were 7 (7%) GISTs, 88 (88%) leiomyomas, 3 (3%) lipomas, and 2 (2%) cysts. Metallic clips and endoloop was applied in 29 (40.8%) EFTR patients and 2 (2%) STER patients. There was no significant difference in total complications between two groups (21.1% vs 22.0%, *P* = 0.89). The most common complication in both groups was electrocoagulation syndrome. All complications were managed successfully by endoscopic methods and conservative treatment.

Subgroup analyses the risk for EFTR

Univariate and multivariate analyses showed that larger tumor size (> 2 cm) and extraluminal growth were significant risk factors for long procedure times (Table 3).

Table 1 Baseline characteristics of the 171 patients with submucosal tumors in gastric cardia treated by endoscopic full-thickness resection and submucosal tunneling endoscopic resection

Patients	EFTR	STER	P value
Age (yr)			0.59
mean ± SD	51.32 ± 12.44	50.29 ± 12.19	
Median (range)	52.00 (43.00-61.00)	51.00 (41.00-59.75)	
Sex			0.01
Male	24 (33.8%)	53 (53.0%)	
Female	47 (66.2%)	47 (47.0%)	
Lesion characteristics			
Size (cm)			0.78
mean ± SD	2.16 ± 1.81	2.09 ± 1.38	
Median (range)	1.50 (1.00-3.00)	1.50 (1.20-2.50)	
Extraluminal growth			0.37
Yes	6 (8.5%)	5 (5.0%)	
No	65 (91.5%)	95 (95.0%)	
Operator level			0.74
Experts	59 (83.1%)	85 (85.0%)	
Trainees	12 (16.9%)	15 (15.0%)	

EFTR: Endoscopic full-thickness resection; STER: Submucosal tunneling endoscopic resection.

Follow-up results

Of the 171 patients with gastric cardiac SETs, seven cases were lost to follow-up. The remaining 164 cases were followed for more than 12 mo. The median follow-up was 28 (range: 16-52.5) mo. All patients did not develop local recurrence or distant metastasis during follow-up.

DISCUSSION

The present work was the first time that the efficacy of EFTR for gastric cardia SETs was studied. Current methods to remove gastric SETs include surgical and ER. ER has several advantages over surgical approaches, such as being minimally invasive and incurring a shorter hospital stay[14,15]. The STER procedure was derived from peroral endoscopic myotomy and was initially reported in 2012[6]. A series of subsequent studies have reported that, compared to ESD, STER has benefits for the removal of SETs, such as maintaining the integrity of the mucosa, faster wound healing, and reduced risks of complications including perforation, extraluminal infection, and esophageal stenosis[16-18]. STER has also been reported as a successful treatment option for SETs located in the cardia or esophagogastric junction[19,20]. The advantages of shorter operative and hospitalization times and reduced cost are described[21].

STER requires the establishment of adequate operating space beyond the tumor in the tunnel. The tumor is then pushed into the distal portion of the submucosal tunnel during resection, separating the tumor from the deep MP and increasing the safety of the operation[22,23]. Performing the operation for SETs in the cardia is more complicated than in other parts owing to its specific anatomic characteristics[24]. There is a significant change in the angle of this gastric muscle layer. Therefore, the formation of the tunnel beyond the tumor requires a greater degree of curvature of the anterior part of the endoscope. Additionally, the gastric cavity is relatively narrow, which greatly increases the difficulty of resection[25,26]. Meanwhile, the blood supply at the cardia and gastric fundus is abundant. Thus, the risk of intraoperative bleeding is high, which also increases the difficulty of the operation[26]. In addition, in the lesser curvature or the anterior aspect of the cardia, when the tumor is located in the deep layer of the MP (or even growing extraluminally), and/or where a submucosal tunnel cannot be established, EFTR is needed.

EFTR, as a technical extension of ESD, offers distinct advantages, particularly when dealing with SETs deeply embedded within the MP layer or exhibiting extraluminal growth patterns. The characteristics of EFTR make it a very suitable form of treatment for SETs[12]. Our center previously reported the successful application of EFTR in 26 gastric SETs without laparoscopic assistance. No gastric bleeding, sign of peritonitis, or abdominal infections/abscesses occurred after EFTR[10]. In addition, we have improved the EFTR procedure by incorporating dental floss and a hemoclip, which facilitate countertraction. This improvement enables better visualization of the submucosal layer, resulting in a reduced

Table 2 A comparison of treatment outcomes between endoscopic full-thickness resection and submucosal tunneling endoscopic resection groups

Outcomes	EFTR	STER	P value
En bloc resection	71 (100%)	97 (97.0%)	0.14
Complete resection	70 (98.6%)	91 (91.0%)	0.04
Procedure time (min)	44.63 ± 28.66	53.36 ± 27.34	0.04
Procedure-related characteristics			
Suturing methods			0.01
Metallic clips	38 (53.5%)	98 (98.0%)	
Metallic clips with endoloop	29 (40.8%)	2 (2.0%)	
Stent	4 (5.6%)	0 (0%)	
Histopathology			0.01
GIST	28 (39.4%)	7 (7.0%)	
Leiomyoma	43 (60.6%)	88 (88.0%)	
Others	0 (0%)	5 (5.0%)	
Complications			0.89
Pneumoperitoneum	0 (0%)	0 (0%)	
Hydrothorax			
Minor hydrothorax	3 (4.2%)	4 (4.0%)	
Major hydrothorax	0 (0%)	0 (0%)	
PEECS	10 (14.1%)	18 (18.0%)	
Delayed bleeding	2 (2.8%)	0 (0%)	
Delayed perforation	0 (0%)	0 (0.0%)	
Follow-up			
Recurrence	0 (0%)	0 (0%)	
Metastasis	0 (0%)	0 (0%)	

EFTR: Endoscopic full-thickness resection; STER: Submucosal tunneling endoscopic resection; GIST: Gastrointestinal stromal tumor; PEECS: Post-endoscopic submucosal dissection electrocoagulation syndrome.

incidence of adverse events in the gastric fundus[11].

Similar to the data from our previous studies, EFTR in the gastric cardia had a 100% en bloc and 98.6% complete resection rate. The complete resection rate was higher than STER (98.6% *vs* 91.0%, *P* < 0.05). Complete ER of SETs is the key to ensuring successful operation and avoiding recurrence[26]. Upper gastrointestinal SETs are composed primarily of leiomyomas and GISTs[27]. GISTs have greater potential for malignancy and should be completely resected. An irregular shape and larger size have been shown to be the risk factors for STERs having piecemeal resection[28]. Most esophageal SETs are regular while the majority of cardiac SETs are irregular and lobulated[8], which makes it more difficult for STERs to be completely resected. Additionally, tumor resection by STER is limited by the diameter of the tunnel. Therefore, oversized tumors cannot be completely resected. Due to the anatomy, the tunnel has a turn at the cardia, which can easily lead to compression of the tumor and tumor rupture. Conversely, EFTR allows full-thickness excision of the complete gastrointestinal wall without a diameter limit and the risk for poor resection margins and residual tumor which increases the accuracy of histopathology measurement to direct future therapy[29]. In a meta-analysis including 952 G-SETs treated with EFTR, it was suggested that EFTR was a highly effective therapeutic option for removing deep G-SETs, with an R0 resection achieved in 99.3% of cases[30]. Therefore, for lesions that are highly suspicious for GIST or lesions that are not clearly diagnosed, EFTR should be recommended to ensure completed resection.

In our study, EFTR had a shorter procedure time than STER (44.63 ± 28.66 *vs* 53.36 ± 27.34 min, *P* < 0.05). Chen revealed that STER was relatively difficult and time consuming when used to resect gastric SETs because of limited space in the established submucosal tunnel[7]. They found that an irregular shape and large size were also risk factors for procedures requiring a long operative time. Therefore, irregular shaped and larger sized SETs were more suitable for EFTR. Additionally, compared to STER, EFTR required the creation of a tunnel. Also, there was no risk of the tumor being too large to rupture in the tunnel, which kept the tumor intact.

Table 3 The association of the clinicopathological characteristics of subepithelial tumors in gastric cardia treated by endoscopic full-thickness resection over the median procedure time

	Univariate analysis		Multivariate analysis	
	OR (95%CI)	P value	OR (95%CI)	P value
Age (yr)		0.37		
< 50	1 (reference)			
≥ 50	1.88 (0.48-7.46)			
Sex		0.41		
Male	1 (reference)			
Female	1.76 (0.46-6.68)			
Size (cm)		0.01		
< 2.0	1 (reference)		1 (reference)	0.02
≥ 2.0	6.58 (1.60-27.09)		3.75 (1.21-11.58)	
Extraluminal growth		0.048		0.04
No	1 (reference)		1 (reference)	
Yes	7.83 (1.02-60.03)		7.64 (1.15-50.83)	
Histopathology		0.42		
Others	1 (reference)			
Leiomyoma	1.85 (0.42-8.17)			
Metallic clips with endoloop		0.05		
No	1 (reference)			
Yes	3.68 (0.98-13.91)			
Operator level		0.19		
Trainees	1 (reference)			
Experts	0.31 (0.05-1.76)			


OR: Odds ratio; 95%CI: 95% confidence interval.

The key of the EFTR procedure is the successful closure of the wall defect after resection to prevent peritonitis and the need for surgical intervention[10]. Although a growing body of evidence has demonstrated that gastrointestinal defects after ER can be effectively managed by endoscopy, the closure of large gastrointestinal defects is still technically demanding for most endoscopists[31,32]. Several clips can close small defects. When the diameter of the defect is larger than the width of the open clip, and before applying metallic clips, the defect can first be reduced by air suction using the “suction-clip-suture” method[10]. If the defect is too large to be closed only by clips, a few new techniques have been used in the stomach, such as nylon loop suturing and the over-the-scope clip[33]. In our study, 53.5% patients underwent closure of the defect with clips. 40.8% patients had defect closure using metallic clips with an endoloop. Four patients with large defects had covered, retrievable self-expandable metallic stents used to close the defect. As we our previous study showed, no leakage occurred[33].

There are also having several limitations. The study was retrospective and was conducted at a single institution. Thus, prospective study will be needed to further verify our views. Additionally, gastric EFTR was first performed our center and center has many experienced surgeons in the field. It may be difficult for other hospitals with less experience to carry out the procedure.

CONCLUSION

In conclusion, EFTR was demonstrated to be a very promising method with which to facilitate complete resection and reduce operation time compared to STER in gastric cardia SETs. GISTs were the most common type of SETs in the cardia. When lesions with a high index of suspicion for GIST are found or there is an unclear diagnosis, EFTR should be recommended to ensure complete resection. EFTR by experienced surgeons was shown to be the better option in cases of gastric cardia SETs > 2 cm or with extraluminal growth.



DOI: 10.4251/wjgo.v15.i12.2111 Copyright ©The Author(s) 2023.

Figure 1 Processes of endoscopic full-thickness resection for gastric cardia subepithelial tumors. A: Endoscopic view of gastric cardia subepithelial tumor; B: Circumferential incision was made as deep as muscularis propria around the lesion with IT knife; C: Incision into serosal layer around the lesion was performed with Hook knife to create active perforation; D: Gastric wall defect was presented after lesion was resected; E: The gastric wound was closed with several metallic clips successfully; F: Resected tumor.

ARTICLE HIGHLIGHTS

Research background

The endoscopic full-thickness resection (EFTR) of cardiac subepithelial tumors (SETs) is still difficult.

Research motivation

To evaluate the safety and efficacy of EFTR for the treatment of gastric cardia SETs.

Research objectives

The objective was the comparison of treatment outcomes between EFTR and submucosal tunnel endoscopic resection (STER), and the factors of difficult of EFTR.

Research methods

We retrospectively analyzed the data of all patients with SET originating from the muscularis propria of the gastric cardia who underwent EFTR or STER from November 2014 to May 2022 at Zhongshan Hospital Fudan University.

Research results

Gastrointestinal stromal tumors were the most common SET. The EFTR group had a higher complete resection rate than the STER group (98.6% *vs* 91.0%, $P < 0.05$) and the procedure time was also shorter in the EFTR group (44.63 ± 28.66 min *vs* 53.36 ± 27.34 , $P < 0.05$). There was no significant difference in total complications between the two groups (21.1% *vs* 22.0%, $P = 0.89$).

Research conclusions

Compared to STER, EFTR for gastric cardia SETs is also safe and effective.

Research perspectives

For patients with suspected cardia gastrointestinal stromal tumor, EFTR can be used to achieve better complete resection. Of course, subsequent prospective studies should be conducted for verification this opinion.

FOOTNOTES

Co-first authors: En-Pan Xu and Zhi-Peng Qi.

Co-corresponding authors: Qiang Shi and Yun-Shi Zhong.

Author contributions: Xu EP and Qi ZP contributed equally to this work; Zhong YS and Shi Q designed the research study; Ren Z, Cai MY, Lyu ZT, Chen ZH and Liu JY performed the research; Xu EP, Qi ZP and Li B analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript. Xu EP and Qi ZP contributed equally to this work as co-first authors. Zhong YS and Shi Q contributed equally to this work as co-corresponding authors. The reasons for designating Zhong YS and Shi Q as co-corresponding authors are threefold. First, the research was performed as a collaborative effort, and the designation of co-corresponding authorship accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. This also ensures effective communication and management of post-submission matters, ultimately enhancing the paper's quality and reliability. Second, the overall research team encompassed authors with a variety of expertise and skills from different fields, and the designation of co-corresponding authors best reflects this diversity. This also promotes the most comprehensive and in-depth examination of the research topic, ultimately enriching readers' understanding by offering various expert perspectives. Third, Zhong YS and Shi Q contributed efforts of equal substance throughout the research process. The choice of these researchers as co-corresponding authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. The are two reasons for designating Xu EP and Qi ZP as co-first authors. First, Qi ZP participated in the writing and revision of the manuscript and provided opinions during the writing process. Furthermore, the data results were analyzed with the help of Qi ZP. In summary, we believe that designating Zhong YS and Shi Q as co-corresponding authors and Xu EP and Qi ZP as co-first authors of is fitting for our manuscript as it accurately reflects our team's collaborative spirit, equal contributions, and diversity.

Supported by National Natural Science Foundation of China, No. 82273025; China Postdoctoral Science Foundation, No. 2022TQ0070 and No. 2022M710759; and Shanghai Municipal Commission of Science and Technology, No. 22JC1403003 and No. 22531903800.

Institutional review board statement: This study was approved by the Institutional Review Board of Zhongshan Hospital (Approval No. B2020-265).

Conflict-of-interest statement: The authors have no conflict of interest to declare.

Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at zhong.yunshi@zs-hospital.sh.cn.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: En-Pan Xu 0000-0001-7341-3437; Zhi-Peng Qi 0000-0002-1792-3595; Bing Li 0000-0002-8727-3591; Ming-Yan Cai 0000-0002-8155-3154; Shi-Lun Cai 0000-0002-5000-9658; Zhen-Tao Lvy 0000-0003-4460-0166; Qiang Shi 0000-0001-9958-2132; Yun-Shi Zhong 0000-0001-8382-3747.

S-Editor: Lin C

L-Editor: A

P-Editor: Xu ZH

REFERENCES

- 1 Cheng HL, Lee WJ, Lai IR, Yuan RH, Yu SC. Laparoscopic wedge resection of benign gastric tumor. *Hepatogastroenterology* 1999; **46**: 2100-2104 [PMID: 10430405]
- 2 Lee HH, Hur H, Jung H, Jeon HM, Park CH, Song KY. Analysis of 151 consecutive gastric submucosal tumors according to tumor location. *J Surg Oncol* 2011; **104**: 72-75 [PMID: 21031420 DOI: 10.1002/jso.21771]
- 3 Akahoshi K, Oya M, Koga T, Shiratsuchi Y. Current clinical management of gastrointestinal stromal tumor. *World J Gastroenterol* 2018; **24**: 2806-2817 [PMID: 30018476 DOI: 10.3748/wjg.v24.i26.2806]
- 4 Ko SY, Lee JS, Kim JJ, Park SM. Higher incidence of gastroesophageal reflux disease after gastric wedge resections of gastric submucosal tumors located close to the gastroesophageal junction. *Ann Surg Treat Res* 2014; **86**: 289-294 [PMID: 24949319 DOI: 10.4174/astr.2014.86.6.289]
- 5 Kim SG, Eom BW, Yoon H, Kook MC, Kim YW, Ryu KW. Necessity of Individualized Approach for Gastric Subepithelial Tumor Considering Pathologic Discrepancy and Surgical Difficulty Depending on the Gastric Location. *J Clin Med* 2022; **11** [PMID: 36012971 DOI: 10.3390/jcm11164733]
- 6 Xu MD, Cai MY, Zhou PH, Qin XY, Zhong YS, Chen WF, Hu JW, Zhang YQ, Ma LL, Qin WZ, Yao LQ. Submucosal tunneling endoscopic resection: a new technique for treating upper GI submucosal tumors originating from the muscularis propria layer (with videos). *Gastrointest Endosc* 2012; **75**: 195-199 [PMID: 22056087 DOI: 10.1016/j.gie.2011.08.018]
- 7 Chen T, Zhou PH, Chu Y, Zhang YQ, Chen WF, Ji Y, Yao LQ, Xu MD. Long-term Outcomes of Submucosal Tunneling Endoscopic

- Resection for Upper Gastrointestinal Submucosal Tumors. *Ann Surg* 2017; 265: 363-369 [PMID: 28059965 DOI: 10.1097/SLA.0000000000001650]
- 8 **Du C**, Chai N, Linghu E, Gao Y, Li Z, Li L, Zhai Y, Lu Z, Meng J, Tang P. Treatment of cardiac submucosal tumors originating from the muscularis propria layer: submucosal tunneling endoscopic resection versus endoscopic submucosal excavation. *Surg Endosc* 2018; 32: 4543-4551 [PMID: 29766300 DOI: 10.1007/s00464-018-6206-0]
 - 9 **Sharzchi K**, Sethi A, Savides T. AGA Clinical Practice Update on Management of Subepithelial Lesions Encountered During Routine Endoscopy: Expert Review. *Clin Gastroenterol Hepatol* 2022; 20: 2435-2443.e4 [PMID: 35842117 DOI: 10.1016/j.cgh.2022.05.054]
 - 10 **Zhou PH**, Yao LQ, Qin XY, Cai MY, Xu MD, Zhong YS, Chen WF, Zhang YQ, Qin WZ, Hu JW, Liu JZ. Endoscopic full-thickness resection without laparoscopic assistance for gastric submucosal tumors originated from the muscularis propria. *Surg Endosc* 2011; 25: 2926-2931 [PMID: 21424195 DOI: 10.1007/s00464-011-1644-y]
 - 11 **Li B**, Shi Q, Qi ZP, Yao LQ, Xu MD, Lv ZT, Yalikong A, Cai SL, Sun D, Zhou PH, Zhong YS. The efficacy of dental floss and a hemoclip as a traction method for the endoscopic full-thickness resection of submucosal tumors in the gastric fundus. *Surg Endosc* 2019; 33: 3864-3873 [PMID: 31376013 DOI: 10.1007/s00464-019-06920-w]
 - 12 **Cai MY**, Martin Carreras-Presas F, Zhou PH. Endoscopic full-thickness resection for gastrointestinal submucosal tumors. *Dig Endosc* 2018; 30 Suppl 1: 17-24 [PMID: 29658639 DOI: 10.1111/den.13003]
 - 13 **Ni L**, Liu X, Wu A, Yu C, Zou C, Xu G, Wang C, Gao X. Endoscopic full-thickness resection with clip- and snare-assisted traction for gastric submucosal tumours in the fundus: A single-centre case series. *Oncol Lett* 2023; 25: 151 [PMID: 36936023 DOI: 10.3892/ol.2023.13737]
 - 14 **Nishida T**, Kawai N, Yamaguchi S, Nishida Y. Submucosal tumors: comprehensive guide for the diagnosis and therapy of gastrointestinal submucosal tumors. *Dig Endosc* 2013; 25: 479-489 [PMID: 23902569 DOI: 10.1111/den.12149]
 - 15 **Kim SY**, Kim KO. Management of gastric subepithelial tumors: The role of endoscopy. *World J Gastrointest Endosc* 2016; 8: 418-424 [PMID: 27298713 DOI: 10.4253/wjge.v8.i11.418]
 - 16 **Song S**, Feng M, Zhou H, Liu M, Sun M. Submucosal Tunneling Endoscopic Resection for Large and Irregular Submucosal Tumors Originating from Muscularis Propria Layer in Upper Gastrointestinal Tract. *J Laparoendosc Adv Surg Tech A* 2018; 28: 1364-1370 [PMID: 30256158 DOI: 10.1089/lap.2017.0607]
 - 17 **Ye LP**, Zhang Y, Mao XL, Zhu LH, Zhou X, Chen JY. Submucosal tunneling endoscopic resection for small upper gastrointestinal subepithelial tumors originating from the muscularis propria layer. *Surg Endosc* 2014; 28: 524-530 [PMID: 24013472 DOI: 10.1007/s00464-013-3197-8]
 - 18 **Gong W**, Xiong Y, Zhi F, Liu S, Wang A, Jiang B. Preliminary experience of endoscopic submucosal tunnel dissection for upper gastrointestinal submucosal tumors. *Endoscopy* 2012; 44: 231-235 [PMID: 22354823 DOI: 10.1055/s-0031-1291720]
 - 19 **Chen H**, Xu Z, Huo J, Liu D. Submucosal tunneling endoscopic resection for simultaneous esophageal and cardia submucosal tumors originating from the muscularis propria layer (with video). *Dig Endosc* 2015; 27: 155-158 [PMID: 24444087 DOI: 10.1111/den.12227]
 - 20 **Liu BR**, Song JT, Kong LJ, Pei FH, Wang XH, Du YJ. Tunneling endoscopic muscularis dissection for subepithelial tumors originating from the muscularis propria of the esophagus and gastric cardia. *Surg Endosc* 2013; 27: 4354-4359 [PMID: 23765425 DOI: 10.1007/s00464-013-3023-3]
 - 21 **Li QY**, Meng Y, Xu YY, Zhang Q, Cai JQ, Zheng HX, Qing HT, Huang SL, Han ZL, Li AM, Huang Y, Zhang YL, Zhi FC, Cai RJ, Li Y, Gong W, Liu SD. Comparison of endoscopic submucosal tunneling dissection and thoracoscopic enucleation for the treatment of esophageal submucosal tumors. *Gastrointest Endosc* 2017; 86: 485-491 [PMID: 27899323 DOI: 10.1016/j.gie.2016.11.023]
 - 22 **Werner YB**, Rösch T. POEM and Submucosal Tunneling. *Curr Treat Options Gastroenterol* 2016; 14: 163-177 [PMID: 27059229 DOI: 10.1007/s11938-016-0086-y]
 - 23 **Zhang Q**, Cai JQ, Xiang L, Wang Z, de Liu S, Bai Y. Modified submucosal tunneling endoscopic resection for submucosal tumors in the esophagus and gastric fundus near the cardia. *Endoscopy* 2017; 49: 784-791 [PMID: 28658679 DOI: 10.1055/s-0043-111236]
 - 24 **Wang S**, Shen L. Efficacy of Endoscopic Submucosal Excavation for Gastrointestinal Stromal Tumors in the Cardia. *Surg Laparosc Endosc Percutan Tech* 2016; 26: 493-496 [PMID: 27846180 DOI: 10.1097/SLE.0000000000000330]
 - 25 **Jang YS**, Lee BE, Kim GH, Park DY, Jeon HK, Baek DH, Kim DU, Song GA. Factors Associated With Outcomes in Endoscopic Submucosal Dissection of Gastric Cardia Tumors: A Retrospective Observational Study. *Medicine (Baltimore)* 2015; 94: e1201 [PMID: 26252277 DOI: 10.1097/MD.0000000000001201]
 - 26 **Wang S**, Luo H, Shen L. Clinical Efficacy of Single-Channel Gastroscopy, Double-Channel Gastroscopy, and Double Gastroscopy for Submucosal Tumors in the Cardia and Gastric Fundus. *J Gastrointest Surg* 2020; 24: 1307-1313 [PMID: 31197688 DOI: 10.1007/s11605-019-04286-x]
 - 27 **Hong JB**, Choi CW, Kim HW, Kang DH, Park SB, Kim SJ, Kim DJ. Endoscopic resection using band ligation for esophageal SMT in less than 10 mm. *World J Gastroenterol* 2015; 21: 2982-2987 [PMID: 25780296 DOI: 10.3748/wjg.v21.i10.2982]
 - 28 **Mao XL**, Ye LP, Zheng HH, Zhou XB, Zhu LH, Zhang Y. Submucosal tunneling endoscopic resection using methylene-blue guidance for cardiac subepithelial tumors originating from the muscularis propria layer. *Dis Esophagus* 2017; 30: 1-7 [PMID: 27671744 DOI: 10.1111/dote.12536]
 - 29 **Li J**, Tang J, Lua GW, Chen J, Shi X, Liu F, Li Z. Safety and efficacy of endoscopic submucosal dissection of large (≥ 3 cm) subepithelial tumors located in the cardia. *Surg Endosc* 2017; 31: 5183-5191 [PMID: 28597288 DOI: 10.1007/s00464-017-5585-y]
 - 30 **Granata A**, Martino A, Ligresti D, Tuzzolino F, Lombardi G, Traina M. Exposed endoscopic full-thickness resection without laparoscopic assistance for gastric submucosal tumors: A systematic review and pooled analysis. *Dig Liver Dis* 2022; 54: 729-736 [PMID: 34654680 DOI: 10.1016/j.dld.2021.09.014]
 - 31 **Yamamoto Y**, Uedo N, Abe N, Mori H, Ikeda H, Kanzaki H, Hirasawa K, Yoshida N, Goto O, Morita S, Zhou P. Current status and feasibility of endoscopic full-thickness resection in Japan: Results of a questionnaire survey. *Dig Endosc* 2018; 30 Suppl 1: 2-6 [PMID: 29658648 DOI: 10.1111/den.13045]
 - 32 **Zhang Y**, Peng JB, Mao XL, Zheng HH, Zhou SK, Zhu LH, Ye LP. Endoscopic resection of large (≥ 4 cm) upper gastrointestinal subepithelial tumors originating from the muscularis propria layer: a single-center study of 101 cases (with video). *Surg Endosc* 2021; 35: 1442-1452 [PMID: 32989549 DOI: 10.1007/s00464-020-08033-1]
 - 33 **Zhang Y**, Yao L, Xu M, Berzin TM, Li Q, Chen W, Hu J, Wang Y, Cai M, Qin W, Xu J, Huang Y, Zhou P. Treatment of leakage via metallic stents placements after endoscopic full-thickness resection for esophageal and gastroesophageal junction submucosal tumors. *Scand J Gastroenterol* 2017; 52: 76-80 [PMID: 27632665 DOI: 10.1080/00365521.2016.1228121]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

